stockrowCareDx, Inc.
CDNA Healthcare Diagnostics & Research
CareDx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $379.8 million, up 13.8% from fiscal 2024.
- Revenue
- +39.3%
- EPS
- +1,133.3%
- Free cash flow
- −68.6%
Quarter to September 2026, against a year earlier
Follow CDNA
Alert me
CareDx, Inc. (CDNA) Revenue
CareDx, Inc.'s revenue for fiscal 2025 was $379.8M, up 13.8% from $333.8M in fiscal 2024. Over the twelve months to 30 September 2026 it was $497.4M. Over the past ten years it has ranged from $28.1M (fiscal 2015) to $379.8M (fiscal 2025) — the current reading is the highest in ten years. CareDx, Inc. ranks 24th of 47 Diagnostics & Research companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $379.8M | 13.79% |
| FY2024 | $333.8M | 19.07% |
| FY2023 | $280.3M | (12.89%) |
| FY2022 | $321.8M | 8.57% |
| FY2021 | $296.4M | 54.22% |
| FY2020 | $192.2M | 51.25% |
| FY2019 | $127.1M | 65.95% |
| FY2018 | $76.6M | 58.45% |
| FY2017 | $48.3M | 18.93% |
| FY2016 | $40.6M | 44.37% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $139.4M | 5.62% |
| Jun 2026 | $131.9M | 12.11% |
| Mar 2026 | $117.7M | 8.59% |
| Dec 2025 | $108.4M | 8.33% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| RDNT RadNet, Inc. compare | $2.3B |
| SHC Sotera Health Company compare | $1.2B |
| NEO NeoGenomics, Inc. compare | $787.8M |
| VCYT Veracyte, Inc. compare | $581.8M |
| CDNA CareDx, Inc. | $497.4M |
| WGS GeneDx Holdings Corp. compare | $454.4M |
| BLLN BillionToOne, Inc. compare | $436.9M |
| ADPT Adaptive Biotechnologies Corporation compare | $298.0M |
| GRAL GRAIL, Inc. compare | $166.6M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on CDNA
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement